Live Breaking News & Updates on Switzerland based lonza

Stay informed with the latest breaking news from Switzerland based lonza on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Switzerland based lonza and stay connected to the pulse of your community

Lonza breaks ground for Pease facility with new partnership and new leadership

Lonza breaks ground for Pease facility with new partnership and new leadership
nhbr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nhbr.com Daily Mail and Mail on Sunday newspapers.

Boston , Massachusetts , United-states , Bedford , New-hampshire , Florida , San-diego , California , Alachua , Americans , Pierre-alain-ruffieux , Paul-briand

Navigating equity markets ahead of a global recession

Health care and technology provide opportunities amid uncertainty, PM says

Japan , Edinburgh , City-of , United-kingdom , China , Scotland , Louis-vuitton , Murdo-maclean , Maclean , Microsoft , Walter-scott-partners-ltd , Walter-scott

+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients

/PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as...

California , United-states , Bern , Switzerland , Netherlands , Spain , Belgium , Belgian , Dutch , Swiss , Patrick-aebischer , Dani-bach

+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients

/PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as...

California , United-states , Bern , Switzerland , Netherlands , Spain , Belgium , Belgian , Dutch , Swiss , Patrick-aebischer , Dani-bach

+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients

+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

California , United-states , Bern , Switzerland , Netherlands , Spain , Belgium , Belgian , Dutch , Swiss , Patrick-aebischer , Dani-bach

Lonza expands solid-form services at Oregon facility

Lonza expands solid-form services at Oregon facility
The company has increased capabilities at its Bend, Oregon location, including its SimpliFiH Solutions first-in-human services for small-molecule drugs.
Switzerland-based Lonza has increased its solid-form selection services offered at its Bend, Oregon site. The expansion is designed to help complement its SimpliFiH Solutions services, which include phase-appropriate drug substance, product development and manufacture.
Michael Grass, head of solid form services for Lonza pharma and Biotech Small Molecules, spoke with Outsourcing-Pharma about the reasons for the expansion and what they might mean for potential customers.
OSP: Could you please share an overview of your SimpliFiH solutions—what offerings are under that umbrella?

Oregon , United-states , Simplifih-solutions , Simplifi-solutions , Lonza-simplifih-solutions , Switzerland-based-lonza , Biotech-small-molecules , Contract-manufacturing-amp-logistics , Preclinical-research , Drug-delivery , Bioavailability-challenge